TCGA-A8-A094-01A-11R-A00Z-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MTORC1_SIGNALING+0.520
- ALLOGRAFT_REJECTION+0.450
- PROTEIN_SECRETION+0.430
- CHOLESTEROL_HOMEOSTASIS+0.420
- INFLAMMATORY_RESPONSE+0.390
- ANDROGEN_RESPONSE+0.360
- IL6_JAK_STAT3_SIGNALING+0.360
- G2M_CHECKPOINT+0.330
- COMPLEMENT+0.310
- INTERFERON_GAMMA_RESPONSE+0.310
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.300
- MYOGENESIS-0.270
- HEDGEHOG_SIGNALING-0.260
- NOTCH_SIGNALING-0.220
- KRAS_SIGNALING_DN-0.150
- WNT_BETA_CATENIN_SIGNALING-0.140
- ESTROGEN_RESPONSE_LATE-0.130
- UV_RESPONSE_DN-0.130
- TGF_BETA_SIGNALING-0.090
- APICAL_SURFACE-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A202-01A-11R-A14M-07 | — | C | 0.841 |
| 2 | BS_2EN3X6HB | high-grade glioma | — | 0.817 |
| 3 | TCGA-C8-A278-01A-11R-A169-07 | — | C | 0.813 |
| 4 | MBCProject_0984_T1_RNA | — | C | 0.790 |
| 5 | TCGA-A2-A0SW-01A-11R-A084-07 | — | C | 0.787 |
| 6 | C3N-02087 | — | cohortA1 | 0.786 |
| 7 | TCGA-AR-A24U-01A-11R-A169-07 | — | C | 0.783 |
| 8 | be297c26-df4c-4ae2-a117-a8c6d1cfb421 | — | — | 0.780 |
| 9 | TCGA-18-3415-01A-01R-0980-07 | — | cohortSQ2 | 0.779 |
| 10 | 27dfc12e-4ed1-4d98-b6af-d4e9cbb96779 | — | — | 0.778 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MTORC1_SIGNALING | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.430 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.420 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |